Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8095290 | 0.98 | HTT (0.52) | HTTSMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL3658650 | 0.88 | HTT (0.62) | HTTSMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL3656048 | 0.88 | HTT (0.59) | HTTSMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL9673101 | 0.87 | HTT (0.61) | HTTSMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL9673119 | 0.87 | HTT (0.61) | HTTSMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL9673095 | 0.87 | HTT (0.61) | HTTSMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL3657694 | 0.86 | HTT (0.59) | HTTSMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL3657063 | 0.86 | HTT (0.56) | HTTSMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL9450633 | 0.85 | HTT (0.58) | HTTSMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL6237053 | 0.81 | ALDH1A1 (0.52) | HTTSMN1; SMN2ALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077126-A1 | Fluorine-Containing Compound, Fluorine-Containing Polymer Compound, Resist Composition, Top Coat Composition And Pattern Formation Method | CENTRAL GLASS COMPANY, LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077126-A1 | Fluorine-Containing Compound, Fluorine-Containing Polymer Compound, Resist Composition, Top Coat Composition And Pattern Formation Method | FRG1, AFF2, FBXL19 | HTT 2917/4885SMN1; SMN2 3403/4885ALDH1A1 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.